Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates.
复制标题
输入核黄素和紫外线处理的浓缩血小板后，缺乏针对血小板新抗原的抗体形成。
DOI：
10.1111/j.1537-2995.2009.02347.x
复制
发表时间：
2009
期刊：
影响因子：
2.9
通讯作者：
Goodrich,RaymondP
中科院分区：
文献类型：
--
作者：
Ambruso,DanielR;Thurman,Gail;Marschner,Susanne;Goodrich,RaymondP
背景：病原体灭活技术为供体筛查和血液检测策略提供了一种潜在的解决方案，可降低输血传播传染病的风险。Mirasol病原体减少技术（PRT）系统（CaridianBCT）使用核黄素和紫外线对核酸进行修饰，减少血液成分中的感染性病原体负荷。本研究评估了接受PRT治疗的血小板（PLT）浓缩物28天的患者血清中出现的新抗原抗体。研究设计和方法：在研究入选时和28天随访访视时，从随机分配接受PRT治疗的PLT浓缩物的患者中以及在研究入选时接受未治疗的PLT的对照受试者中获得血清标本。采集未经处理和经PRT处理的PLT的PLT样本。合并每例患者的PLT样本进行分析。使用改良的Capture-P测定法测定患者血清中是否存在针对新抗原的抗体。使用PAK和PAK 12技术确定特定患者样本中自身抗体或同种抗体的存在。结果：对44例接受PRT治疗的PLT患者进行了评价;这些患者均未表现出新抗原抗体。1例患者表现出抗人PLT抗原（HPA）-5 b的PLT同种抗体和对糖蛋白Ia/IIa的自身反应性，与研究开始时的同种抗体一致，但在研究间隔结束时不一致。在对照组评估的22例患者中，检测到一种具有HPA-5 b反应性的同种抗体。结论：接受PRT治疗的PLT浓缩物的患者未显示出针对新抗原的抗体，这表明新抗原形成不是该病原体减少过程的关键副作用。
BACKGROUND:Pathogen inactivation technologies provide a potential solution to donor screening and blood testing strategies reducing the risk of transfusion‐transmitted infectious diseases. The Mirasol pathogen reduction technology (PRT) system (CaridianBCT) uses riboflavin and UV light to introduce modifications in nucleic acids, reducing the infectious pathogen load in blood components. This study evaluated serum of patients who received PRT‐treated platelet (PLT) concentrates over a time period of 28 days for the appearance of antibodies to neoantigens on PLTs.STUDY DESIGN AND METHODS:Serum specimens were obtained at study inclusion and at the 28‐day follow‐up visit from patients randomly assigned to receive PRT‐treated PLT concentrates and at study inclusion of control subjects receiving untreated PLTs. PLT samples from untreated and PRT‐treated PLTs were collected. PLT samples for each patient were pooled for the analysis. The presence of antibodies in patient serum to neoantigens was determined with a modified Capture‐P assay. The presence of auto‐ or alloantibodies in specific patient samples was determined with PAKAUTO and PAK 12 techniques.RESULTS:Forty‐four patients receiving PRT‐treated PLTs were evaluated; none of these patients demonstrated antibodies to neoantigens. One patient demonstrated a PLT alloantibody to human PLT antigen (HPA)‐5b and autoreactivity to glycoprotein Ia/IIa, consistent with an alloantibody at the beginning, but not at the end of the study interval. Of 22 patients evaluated in the control group, one alloantibody with HPA‐5b reactivity was detected.CONCLUSION:Patients receiving PRT‐treated PLT concentrates did not demonstrate antibodies to neoantigens, suggesting that neoantigen formation is not a critical side effect of this pathogen reduction process.